Related Experiment Video
Updated: Jul 10, 2026
10:26
Using In Vitro Live-cell Imaging to Explore Chemotherapeutics Delivered by Lipid-based Nanoparticles
Published on: November 1, 2017
[Lymphangiosarcoma treated with liposomal doxorubicin (Caelyx)]
E Verdier1, P Carvalho, P Young
1Clinique Dermatologique, CHU, Rouen, France. verdiereva@yahoo.fr
Annales De Dermatologie Et De Venereologie
|November 6, 2007
Summary
Liposomal doxorubicin showed significant tumor regression in an elderly patient with lymphangiosarcoma. This chemotherapy offers a less toxic alternative for managing this rare cancer.
Area of Science:
- Oncology
- Medical Case Reports
Background:
- Lymphangiosarcoma is a rare, aggressive malignancy with a poor prognosis.
- Traditional anthracycline chemotherapy is often poorly tolerated by patients.
- Liposomal doxorubicin presents a potentially less toxic alternative.
Observation:
- A 70-year-old female with post-mastectomy lymphedema developed a painful, bleeding lymphangiosarcoma.
- Due to extensive tumor spread, surgical intervention was not feasible.
- The patient received liposomal doxorubicin at 50 mg/m2.
Findings:
- Marked tumor regression was observed after the first chemotherapy course.
- Significant reduction (90%) in tumor mass was achieved after five courses.
- Symptomatic relief, including cessation of pain and bleeding, was noted.
Implications:
- Liposomal doxorubicin demonstrated a dramatic response in this lymphangiosarcoma case.
- This agent may be a viable treatment option for lymphangiosarcoma, especially in elderly patients.
- Further investigation into liposomal doxorubicin for lymphangiosarcoma is warranted.
